Advanced Enzyme’s subsidiary to acquire Evoxx
Mumbai: Advanced Enzyme Technologies announced on Thursday that the company’s wholly-owned subsidiary, Advanced Enzymes Europe B.V has entered into a definite agreement to acquire Evoxx Technologies GmbH.
The company is acquired for a total consideration of Euro 7.65 million and this acquisition is expected to be completed by mid of August 2017
The target entity belongs to development and production of enzymes and certain nutritional carbohydrates. Evoxx reported a total turnover of approx Euro 3 million.
On completion of this acquisition, Evoxx will become direct subsidiary of Advanced Enzymes Europe B.V and indirect subsidiary of Advance Enzyme Technologies.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd